Charles River Laboratories International, Inc. United States District Court – District of Massachusetts Class Period: May 5, 2020 – february 21, 2023 Attorneys: Frederic S. FoxFFox@kaplanfox.comDonald R. HallDHall@kaplanfox.comJeffrey P. Campisi JCampisi@kaplanfox.comPamela MayerPMayer@kaplanfox.com Documents: Amended Complaint Kaplan Fox Notifies Investors of Complaint Filed Against Charles River Laboratories International, Inc. New York, NY – A complaint was filed against Charles River Laboratories International, Inc. alleging the company and its executives concealed illegal importation of nonhuman primates used for research. The complaint was filed in Massachusetts federal court against Charles River, James Foster, David Smith and Flavia Pease. This is a class action on behalf of persons and entities that purchased or otherwise acquired Charles River securities between May 5, 2020 and February 21, 2023, inclusive (the Class Period). The Complaint states, “Charles River is a full-service, non-clinical global drug development partner with a mission to create healthier lives. The Company has three reporting segments: Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions. The Discovery and Safety Assessment segment accounts for approximately 60% of the Company’s total revenue and offers, among other things, safety assessment studies required for regulatory submission of therapeutic solutions.” The Complaint goes on to allege, “On February 22, 2023, before the market opened, Charles River revealed that it had received a subpoena from the U.S. Department of Justice (“DOJ”) relating to an ongoing investigation in conjunction with the U.S. Fish and Wildlife Service (“USFWS”) into the supply chain and illegal importation of non-human primates for research. The Company noted that it was voluntarily suspending shipments of primates from Cambodia, which would negatively impact its earnings for the year and would reduce revenue growth by 200 basis points to 400 basis points.” WHY CONTACT KAPLAN FOX Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. If you have any questions about this Notice, your rights, or your interests, please contact: Jeffrey P. CampisiKAPLAN FOX & KILSHEIMER LLP800 Third Avenue, 38th FloorNew York, New York 10022(212) 329-8571E-mail: jcampisi@kaplanfox.com Connect with Kaplan Fox. Receive a complimentary case review now. Contact Us Inari Medical, Inc. See the Case Barclays iPath Series B S&P 500 VIX Short-Term Futures ETN See the Case Charles River Laboratories International, Inc. See the Case Digital Currency Group, Inc. See the Case Spectrum Pharmaceuticals, Inc. See the Case Co-Diagnostics, Inc. See the Case Vale SA See the Case Geron Corporation See the Case Hecla Mining Company See the Case Textron Inc. See the Case Ambac Financial Group Securities Litigation See the Case Citigroup CSO Hedge Fund Class Action See the Case
